Publications/Presentations/Grants
Updated: August 1, 2007
Recent Key Publications:
Cancer:
Sabbadini, R.A.
Targeting sphingosine-1-phosphate for cancer therapy.
British J. Cancer: 95:1131-5 2006.
Visentin, B., Vekich, J., Sibbald B., Moreno, K., Cavalli, A., Garland, W., Lu, Y., Mills, G.
and Sabbadini, R. (2006)
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic
in reducing growth, invasion, and angiogenesis in multiple tumor lineages.
Cancer Cell, Volume 9, Issue 3 March 2006, 225-238. http://www.cancercell.org
Heart Disease:
Deutschman D, Carstens JS, Klepper RE, Smith WS, Page MT, Young TR, Gleason L, Nakajima N
& Sabbadini RA.
Predicting coronary artery disease using serum sphingosine-1-phosphate.
Am. Heart J. 146: 62-68. 2003.
O'Brien, N, W., M. Guo, C. C. Glembotski, and R. A. Sabbadini.
Molecular identification of rat FAN and its role in hypoxia reoxygenation induced cell
death in cardiomyocytes.
Circ. Res., 92: 589-91. 2003.
Recent Grant Activity
NCI R43 CA110298-01 7/1/04-6/31/05
Anti-sphingolipid antibodies for the treatment of cancer
The goal of this Phase I SBIR grant was to test the ability of monoclonal antibodies to sphingosine-1-phosphate to mitigate tumor angiogenesis, metastatic potential and cancer cell proliferation in experimental animal models.
NCI 2R44CA110298-2 5/05-8/07
Anti-sphingolipid antibodies for the treatment of cancer
The goal of this Phase II grant is to develop a humanized anti-S1P antibody product for the treatment of human cancer in anticipation of filing an IND.
NHLBI R43 HL075906-01 3/1-2/28/05
The role of sphingolipids in cardiac ischemia.
The goal of this work was to prevent cell death in cardiac tissue by interfering with the sphingolipid signaling system.
NCI 1R43EY018020-01 (Phase I) 2/01/07-1/31/08
Sphingomab mitigates the multiple pathologies of age-related macular degeneration.
The goal of this Phase I SBIR is to determine if sphingolipids are involved in the macular degeneration.
2R44EY018020-02 12/1/07 12/01/09 Priority score 161
Sphingomab mitigates the multiple pathologies of age-related macular degeneration.
The goal of this Phase II SBIR is to conduct safety and efficacy studies in non-human primates in anticipation of filing an IND. This grant has not yet been awarded, but the excellent priority score suggests that it will be.
Key Scientific Presentations
Invited speaker International Society of Heart Research (ISHR) Bologna, Italy
June 21-26, 2007
Invited Speaker, FASEB Summer Research Conference on lysophospholipids in health and disease, Tucson, AZ
June 14, 2007
Invited Speaker, INSERM Istitut Universitaire d'Hematologie, Hopital Saint-Louis, Paris, France
September 18, 2006
Invited Speaker, U.S. Patent and Trademark Office TechFair
April 17, 2006
Invited Seminar Speaker, University of Arkansas School of Medicine
March 13, 2006
Invited Speaker, Tarzana Regional Medical Center
October 21, 2005
Invited Speaker, Eicosanoids and other bioactive lipids in cancer, inflammation
and related disease 9th International Conference
September 11 - 14, 2005
Invited Speaker, University of Hong Kong Medical School
September 1, 2005
Invited Speaker, Department of Experimental Biomedical Science University of
Padova, Italy,
November 22, 2004
Invited Speaker, MD Anderson Cancer Center
October 28, 2004
Invited Speaker, FASEB Summer Conference on Lysophospholipids and Related
Bioactive Lipids in Biology and Diseases, Snowmass Village, Colorado
June 28-July 3, 2003
Recent Published Abstracts from Scientific Meetings
Matteo R, Hiraiwa M, Visentin B, Gentile A, Moreno K, Shestowsky W, Garland W, Mills G, Hansen G, Sabbadini R.
Anti-tumor effects of several monoclonal antibodies that bind all the principal isoforms of lysophosphatidic acid.
American Association for Cancer Research, 2007 Annual Meeting
Stoller G, Swaney JS, Hansen G, Cunningham B, Shestowsky W, Moreno K, Cavalli A, Garland W, Sabbadini RA, Caballero S, Grant M.
A Novel Humanized Monoclonal Antibody Against The Bioactive Lipid Sphingosine-1-Phosphate Strongly Inhibits Choroidal Neovascularization (CNV) In A Murine Model.
The Association for Research in Vision and Ophthalmology, 2007 Annual Meeting
Swaney JS, Hansen G, Garland W, Sabbadini RA and Stoller GL.
Sphingosine-1-phosphate is a Novel Lysolipid Mediator of Epithelial-to-Mesenchymal Transition by Human Retinal Pigmented Epithelial (RPE) Cell.
The Association for Research in Vision and Ophthalmology, 2007 Annual Meeting
Hansen G.
Engineering of a Therapeutic Antibody to Sphingosine-1-Phosphate for Cancer Therapy.
The Protein Engineering Summit, 2007 Annual Meeting
Hansen G, Visentin B, Matteo R, Swaney J, Cavalli A, Hiraiwa M, Garland W, Sabbadini R.
Therapeutic Potential of an Anti-S1P Monoclonal Antibody.
Charleston Ceramide Conference, 2007 Annual Meeting
Thompson J, Moreno K, Matteo R, Cunningham B, Hiraiwa M, Hansen G, Sabbadini.
Rapid and convenient assay for the detection of S1P in biological samples.
Summer Research Conference on lysophospholipids in health and disease, Tuscon, AZ June 14, 2007
Cavalli, A, B. Visentin, A. Gentile, Wm Garland, R. Sabbadini and G. Hansen.
Anti-Sphingosine 1-phosphate Antibody to Treat Cancer.
FASEB Summer Research Conference, Tuscon, AZ June 2007
Swaney JS, Gellings-Lowe N, Stoller G, Garland W, Caballero S, Grant M, Hansen G, Sabbadini RA.
An Emerging Role of Sphingosine-1-Phosphate in Tissue Fibrosis: Therapeutic Potential of an Anti-S1P monoclonal Antibody.
Keystone Symposium, Molecular Mechanisms of Fibrosis: From Bench to Bedside, Mar 11 - 15, 2007
Stoller GL, Caballero S, Swaney JS, Sabbadini RA, Garland W, Cavalli A, Grant M.
Antagonism of S1P Strongly Inhibits Choroidal Neovascularization (CNV) and Subretinal Fibrosis in a Murine Model.
The American Academy of Ophthalmologists, 2006 Annual Meeting
Sabbadini, R.A., et al.
The pleiotropic effects of S1P are mitigated by an anti-S1P mAb in multiple murine models of cancer, age-related macular degeneration and heart failure.
Fifth Annual Meeting of the Sphingolipid Club, Nov. 2-4., 2006 Calella de la Costa, Spain
Hansen G.
Novel non-protein targets for cancer therapy.
Honeycomb Connect Conference, People in Life Sciences, Sep 2006 Annual meeting
Sibbald, B R. Matteo and R. Sabbadini.
Sphingosine-1-Phosphate induced tumor growth and metastatic potential in multiple
myeloma is mitigated with an anti-S1P mAb (SphingomabTM)
American Association of Cancer Researchers meeting, Washington, DC April, 2006.
Zanin M, Germinario E, Biral D, Sabbadini RA, Betto R, Danieli-Betto D.
Sphingolipid signaling in denervated skeletal muscle.
Second meeting of the Interuniversity
Institute of Myology. Casciana Terme - Pisa, October 21-23, 2005
Gellings Lowe, N., M. Sussman, and R. Sabbadini.
Increased Functional Recovery after Myocardial Infarction in Mice Treated with
Anti-Sphingosine-1-Phosphate Antibody.
9th International Conference on Eicosanoids and other Bioactive Lipids in Cancer, Inflammation and Related Disease.
San Francisco, CA Sept, 2005.
Visentin, B., J. Vekich, J., B. Sibbald, A. Cavalli, Wm. Garland, K. Moreno, R. Matteo, V. Kumar,
G. Mills and R. Sabbadini.
Tumorigenic and angiogenic effects of S1P are mitigated by an anti-S1P mAb in
multiple murine models of cancer.
9th International Conference on Eicosanoids and other Bioactive Lipids in Cancer, Inflammation
and Related Disease. San Francisco, CA Sept, 2005.
Vekich, J., B. Sibbald, B.Visentin, A. Cavalli and R. Sabbadini.
Sphingosine-1-phosphate's tumorigenic effects are mitigated by anti-S1P
monoclonal antibodies.
American Association of Cancer Researchers meeting, Anaheim, CA April, 2005.
Other Publications in the Sphingolipid Arena
Sabbadini RA, Betto R, Teresi A, Fachechi-Cassano G & Salviati G (1992).
The effects of sphingosine on sarcoplasmic reticulum membrane calcium release.
J Biol Chem 267(22), 15475-15485.
Sabbadini R, Mc Nutt Wm, Jenkins G, Betto R & Salviati G (1993).
Sphingosine is endogenous to cardiac and skeletal muscle.
Biochim Biophys Res Comm 193(2), 752-758.
Dettbarn C, Betto R, Salviati G, Palade P, Jenkins GM & Sabbadini RA. (1994).
Modulation of cardiac SR ryanodine receptor by endogenous sphingosine.
J Mol Cell Cardiol 26, 229-242.
Webster R, Sabbadini R, Dettbarn C & Paolini P. (1994).
Sphingosine inhibition of cardiac myocyte sarcoplasmic reticulum calcium release.
J Mol Cell Cardiol 26, 1273-1290.
McDonough P, Yasui K, Betto R, Salviati G, Glembotski C, Palade P & Sabbadini R (1994).
Control of Cardiac Ca2+ levels: Inhibitory actions of sphingosine on Ca 2+ transients
and L-channel conductance.
Circ Res 75, 981-989.
Dettbarn C, Betto R, Salviati G, Sabbadini R & Palade P (1995).
Involvement of ryanodine receptors in sphingosyl phosphorylcholine-induced calcium
release from brain microsomes.
Brain Res 669:79-85.
Krown K, Yasui K, Brooker M, Dubin A, Nguyen C, Harris G, McDonough P, Glembotski C,
Palade P & Sabbadini R (1995).
TNF- a receptor expression in rat cardiac myocytes: TNF a inhibition of L-type Ca 2+
current and Ca 2+ transients.
FEBS Letters 376:24-30.
Krown K, Page MT, Nguyen C, Gutierrez V, Comstock KL, Quintana PJE, Glembotski CC &
Sabbadini RA (1996).
TNF a -induced apoptosis in cardiac myocytes: Involvement of the sphingolipid
signaling cascade in cardiac cell death.
J Clin Invest 98:2854-2865.
Betto R, Teresi A, Turcato F, Salviati G, Sabbadini R, Krown K, Glembotski C, Dettbarn C,
Yasui K & Palade P (1997).
Sphingosylphosphorylcholine modulates the ryanodine receptor calcium release
channel of cardiac sarcoplasmic reticulum membranes.
Biochem J 322:327-333.
Comstock KL, Krown KA, Page MT, Martin D, Ho P, Pedraza M, Castro EN, Nakajima N,
Glembotski CC, Quintana PJ & Sabbadini R (1998).
LPS-induced TNF- a release from and apoptosis in rat cardiomyocytes: Obligatory
role of CD14 in mediating the LPS response.
J Mol Cell Cardiol 30:2761-2775.
Ghosh N, Sabbadini R & Chatterjee S (1998).
Identification, partial purification and localization of a neutral sphingomyelinase in
rabbit skeletal muscle: neutral sphingomyelinase in skeletal muscle.
Mol Cell Biochem 189: 161-168. 1998.
Sabbadini RA, Danielli-Betto D & Betto R (1999).
Role of sphingolipids in muscle function.
It J of Neurol Sci 20:423-430.
Nakajima NJ, Ligutti A, Cavalli AL, Biral D, Glembotski CC, McDonough PM, Ho PD, Betto R,
Sandona D, Palade PT, Dettbarn CA, Klepper RE & Sabbadini RA (2000).
Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium
deregulation in response to sphingosine-1-phosphate.
Eur J Biochem 267: 5679-5686.
Page MT, Quintana PJE, Ligutti JA & Sabbadini RA (2000).
Cell death in cultured adult rat cardiomyocytes: use of the COMET assay to distinguish
apoptosis from necrosis.
Basic and Appl Myology 10: 159-170.
Dalla Libera L, Sabbadini R, Ravara B, Sandri M, Betto R & Vescovo G (2001).
Apoptosis in the skeletal muscle of rats with heart failure is associated with increase
serum levels of TNF- a and sphingosine.
J Mol Cell Cardiol 31: 1871-1878.
Liguti, J., Nakajima, N.,Cavalli, A.L, Betto, R., Biral, D., Sabbadini, R. (2000)
G protein-coupled receptors, calcium deregulation and apoptosis in the heart.
Basic Appl. Myol. 10: 75-76.
Cavalli A, O'Brien N, Barlow S, Betto R, Glembotski C, Palade P & Sabbadini, R.
Expression and functional characterization of SCaMPER: A calcium channel of
cardiomyocytes.
Am J Physiol. 284: C780-C790. 2003.
Cavalli, A.L. J. A. Ligutti, N.M. Gellings, E. Castro, M. T. Page, R. E. Klepper, and
R. A. Sabbadini.
The role of TNF- a and sphingolipid signaling in cardiac hypoxia: Evidence that
cardiomyocytes release TNF a and sphingosine.
Basic and Appl. Myology 12: 159-167. 2002. http://www.bio.unipd.it/~bam/02493Cavalli.pdf